InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe, Asia, and internationally. It offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. The company also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions. In addition, it offers hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company sells and markets its products in the United States, Canada, the United Kingdom, Ireland, Spain, Portugal, France, Belgium, Luxemburg, Italy, Germany, Austria, Japan, Australia, and India through distributors. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. The company was incorporated in 2008 and is headquartered in Yokne'am, Israel.…
InMode: Q3 Earnings Snapshot
InMode (NASDAQ: INMD) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 660 employees.
The shares were at 12.42 USD on 20 November 2026, down 15.0% over 52 weeks. Its 52-week range is 12.40 USD to 16.67 USD, and it trades at the bottom of that range.
At a market capitalisation of 714.70M USD, it trades at 10.4 times trailing earnings and 9.1 times forward earnings. The median trailing P/E of its 19 largest Medical Devices peers is 25.5, a discount of 59% for INMD.
InMode reports return on equity of 13.7%, an operating margin of 18.0% and revenue down 1.1% year over year.
It holds more cash than debt, a net cash position of 509.15M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 3 analysts cover the stock, with an average rating of Hold; their mean price target of 14.67 USD is 18.1% above the current price. The next earnings report is expected on 9 February 2027.